Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo

Contineum Therapeutics, Inc.

43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).
COAP patients: mean PI-NRS change -1.60 (PIPE-791) vs -1.27 (placebo) in Treatment Period 1.
CLBP patients: mean PI-NRS change -1.33 (PIPE-791) vs -0.55 (placebo) in Treatment Period 1.
Exploratory endpoints (≥30% pain reduction, KOOS) further supported positive PI-NRS trends.
Company plans further evaluation of PIPE-791 for chronic pain; also in Phase 2 PROPEL-IPF (IPF).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.